<i>Immuno-</i>μSARS2 Chip: A Peptide-BasedMicroarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints

A multiplexed microarray chip (<i>Immuno</i>-μSARS2) aiming at providing information on the prognosis of the COVID-19 has been developed. The diagnostic technology records information related to the profile of the immunological response of patients infected by the SARS-CoV-2 virus. The diagnostic technology delivers information on the avidity of the sera against 28 different peptide epitopes and 7 proteins printed on a 25 mm² area of a glass slide. The peptide epitopes (12–15 mer) derived from structural proteins (Spike and Nucleocapsid) have been rationally designed, synthesized, and used to develop <i>Immuno</i>-μSARS2 as a multiplexed and high-throughput fluorescent microarray platform. The analysis of 755 human serum samples (321 from PCR+ patients; 288 from PCR– patients; 115 from prepandemic individuals and classified as hospitalized, admitted to intensive-care unit (ICU), and <i>exitus</i>) from three independent cohorts has shown that the chips perform with a 98% specificity and 91% sensitivity identifying RT-PCR+ patients. Computational analysis utilized to correlate the immunological signatures of the samples analyzed indicate significant prediction rates against <i>exitus</i> conditions with 82% accuracy, ICU admissions with 80% accuracy, and 73% accuracy over hospitalization requirement compared to asymptomatic patients’ fingerprints. The miniaturized microarray chip allows simultaneous determination of 96 samples (24 samples/slide) in 90 min and requires only 10 μL of sera. The diagnostic approach presented for the first time here could have a great value in assisting clinicians in decision-making based on the information provided by the <i>Immuno</i>-μSARS2 regarding progression of the disease and could be easily implemented in diagnostics of other infectious diseases.